|1.||Puri, Raj K: 11 articles (08/2010 - 02/2002)|
|2.||Croteau, David: 8 articles (01/2011 - 02/2005)|
|3.||Sampson, John H: 7 articles (01/2011 - 01/2006)|
|4.||Kunwar, Sandeep: 6 articles (01/2011 - 02/2005)|
|5.||Pedain, Christoph: 6 articles (01/2011 - 01/2006)|
|6.||Chang, Susan M: 5 articles (01/2011 - 02/2005)|
|7.||Puri, R K: 5 articles (11/2001 - 06/2000)|
|8.||Husain, Syed R: 3 articles (08/2010 - 08/2002)|
|9.||Sherman, Jeffrey W: 3 articles (11/2007 - 01/2006)|
|10.||Pastan, Ira: 3 articles (07/2007 - 02/2007)|
08/15/2001 - "or intratumoral administration of IL13-PE38QQR given daily or on alternate days for 3-5 days showed dramatic tumor response with complete remission in intratumorally injected tumors in both IL-13Ralpha2 chain-positive and -negative but transfected with IL-13Ralpha2 chain head and neck tumor implanted s.c. "
02/01/2005 - "Patients were treated in two groups: Group 1 patients received IL13-PE38QQR before and after tumor resection; Group 2 patients received infusion only after tumor resection. "
05/01/2004 - "Interstitial infusion of IL13-PE38QQR, a tumor specific, chimeric cytotoxin, into the rat brain stem was performed in an effort to assess safety. "
06/01/2000 - "Intravenous administration of IL13-PE38QQR also suppressed tumor growth; however, complete responses were not observed. "
06/01/2000 - "Systemic and loco regional administration of IL13-PE38QQR in immunodeficient mice with established human KS tumors produced remarkable antitumor activity. "
03/01/2007 - "Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group."
01/01/2003 - "Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies."
06/01/2008 - "Cintredekin besudotox in treatment of malignant glioma."
01/01/2006 - "Cintredekin besudotox was administered via intraparenchymal CED after resection of supratentorial recurrent malignant glioma. "
01/01/2003 - "Three phase I studies have been initiated to investigate IL13-PE38QQR as an anti-tumor agent for the treatment of patients with recurrent malignant gliomas. "
|4.||Acquired Immunodeficiency Syndrome (AIDS)
|5.||Glioblastoma (Glioblastoma Multiforme)
04/15/2001 - "On the basis of these studies, we have initiated a Phase I clinical trial using IL13-PE38QQR in patients with recurrent glioblastoma. "
01/01/2011 - "The PRECISE study used convection enhanced delivery (CED) to infuse IL13-PE38QQR in patients with recurrent glioblastoma multiforme (GBM) and compared survival to Gliadel Wafers (GW). "
08/01/2010 - "Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma."
08/01/2010 - "Convection-enhanced delivery (CED) of cintredekin besudotox (CB) was compared with Gliadel wafers (GW) in adult patients with glioblastoma multiforme (GBM) at first recurrence. "
09/01/2000 - "Here we demonstrate that pancreatic cancer, renal cell carcinoma, head and neck cancer, and glioblastoma cell lines that were genetically altered to express high levels of IL-13R alpha chain increase their binding affinity for IL-13, and increase their sensitivity to IL13-PE38QQR by at least 6-fold to 1000-fold compared with mock-transfected control cells. "
|1.||Interleukin-13 Receptors (Interleukin 13 Receptor)
|2.||Pseudomonas aeruginosa toxA protein
|3.||decanedioic acid- 4,4'- (1,3- propanediylbis(oxy))bis(benzoic acid) copolymer (Gliadel)